| Market Capitalization (Millions $) |
2 |
| Shares
Outstanding (Millions) |
1 |
| Employees |
111 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
1 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Galmed Pharmaceuticals Ltd is a pharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of liver diseases. The company is based in Israel and operates globally.
Galmed is primarily known for its lead product candidate, Aramchol, which is under investigation for the treatment of non-alcoholic steatohepatitis (NASH), a progressive form of fatty liver disease. Aramchol has shown promising results in clinical trials and has the potential to address the large unmet medical need in the NASH market.
In addition to Aramchol, Galmed is also engaged in the development of other drug candidates targeting liver diseases, including fibrosis and primary sclerosing cholangitis. The company's pipeline is focused on addressing various stages and aspects of liver disease progression.
Galmed has strategic partnerships and collaborations with other pharmaceutical companies to explore the potential of its drug candidates in combination therapies and to expand its global reach. The company has a strong commitment to research and development, aiming to bring innovative therapies to patients with liver diseases.
Company Address: 16 Abba Hillel Road Ramat Gan 5250608
Company Phone Number: 693.8448 Stock Exchange / Ticker: NASDAQ GLMD
|
0.38% 